Dried Blood Spot (DBS) technology is well recognized as a cost effective, simple and reliable alternative to conventional liquid sampling methods for a wide range of applications. During the current pandemic, serological testing is emerging as a powerful solution to improve our understanding of COVID-19 exposure, transmission and immune response in patients previously infected with SARS-CoV-2. However, in the midst of the pandemic restrictions, large-scale testing is limited by the need for trained healthcare workers and quarantines with many patients advised to stay home. Ahlstrom-Munksjö Specimen Collection Cards allowing capillary blood self-sampling and simplified transport to laboratories for analysis could provide a reliable alternative. In this study, both DBS and liquid serum samples were tested using one serological assay to evaluate the usability of DBS with Ahlstrom-Munksjö BioSample collection cards for the detection of anti-SARS-CoV-2 antibodies.
Fill in the form below to download the full white paper!